← Back to Search

Other

LY3437943 for Obesity

Verified Trial
Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 48
Awards & highlights

Study Summary

This trial will test the effects of the drug LY3437943 on weight loss in obese or overweight people. The trial will last 18 months and include up to 18 visits.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Mean Change From Baseline in BMI
Mean Change From Baseline in Body Weight
Mean Change From Baseline in Waist Circumference
+4 more

Side effects data

From 2022 Phase 2 trial • 281 Patients • NCT04867785
20%
Decreased appetite
20%
Nausea
15%
Diarrhoea
11%
Constipation
11%
Vomiting
11%
Upper respiratory tract infection
11%
Urinary tract infection
7%
Fatigue
7%
Dyspepsia
4%
Anaemia
4%
Covid-19
4%
Lipase increased
4%
Dizziness
4%
Weight decreased
2%
Cellulitis
2%
Diabetic ketoacidosis
2%
Abdominal pain
2%
Eructation
2%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3437943 (2 mg)
8 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: 8 mg LY3437943 (4 mg)Experimental Treatment1 Intervention
Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
Group II: 8 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
Group III: 4 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
Group IV: 4 mg LY3437943Experimental Treatment1 Intervention
Participants received 4 mg LY3437943 administered as SC injection QW.
Group V: 12 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
Group VI: 1 milligram (mg) LY3437943Experimental Treatment1 Intervention
Participants received 1 mg LY3437943 administered as SC injection QW.
Group VII: PlaceboPlacebo Group1 Intervention
Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3437943
2022
Completed Phase 2
~950

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,613 Previous Clinical Trials
3,200,591 Total Patients Enrolled
53 Trials studying Obesity
40,490 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
404,914 Total Patients Enrolled
36 Trials studying Obesity
20,209 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Missouri
Florida
Other
California
How old are they?
18 - 65
What site did they apply to?
Palm Research Center Tenaya
Diablo Clinical Research, Inc.
Other
Velocity Clinical Research, Panorama City
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
3+
1
0

What questions have other patients asked about this trial?

When can I start? How long does the screening visits take ? How often do you have to travel to the site?
PatientReceived no prior treatments
How often to screening visits need to happen? How long does this study take place and how many times do I travel to Illinois?
PatientReceived no prior treatments

Why did patients apply to this trial?

Just need help! To loose weight. To check the study. To Lois e my weight. Need ti lose weight.
PatientReceived 2+ prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Phone Call
Most responsive sites:
  1. Velocity Clinical Research, Panorama City: < 24 hours
Recent research and studies
clinicaltrials.govStudy
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
2021. "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04881760.
~86 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top